KYTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.906

+2.92%

-0.887

-13.83%

-0.890

-8.25%

Estimates Revision

Stock Price

Go Up

+25.49%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

24.00

High

31.00

Current: 0.000

Low

20.00

Averages

24.00

High

31.00

Wells Fargo

Overweight

maintain

$31 -> $33

2025-12-16

Reason

Wells Fargo

Price Target

$31 -> $33

2025-12-16

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Kyverna Therapeutics to $33 from $31 and keeps an Overweight rating on the shares. The firm notes that mivocabtagene-autoleucel's stiff person syndrome data is in line with its bull case and it believes shares should trade up into the mid-teens on the data. Wells thinks mivocabtagene-autoleucel could potentially benefit from priority review/CNPV given the high unmet need in stiff person syndrome.

Morgan Stanley

Michael Ulz

Overweight

maintain

$25 -> $33

2025-12-15

Reason

Morgan Stanley

Michael Ulz

Price Target

$25 -> $33

2025-12-15

maintain

Overweight

Reason

Morgan Stanley analyst Michael Ulz raised the firm's price target on Kyverna Therapeutics to $33 from $25 and keeps an Overweight rating on the shares. Top line data from the Phase 2 registrational study of mivocabtagene autoleucel in stiff person syndrome confirm robust, consistent activity and favorable tolerability, says the analyst, who views the results as "very positive."

Leerink

Outperform

maintain

$25 -> $32

2025-12-15

Reason

Leerink

Price Target

$25 -> $32

2025-12-15

maintain

Outperform

Reason

Leerink raised the firm's price target on Kyverna Therapeutics to $32 from $25 and keeps an Outperform rating on the shares after the company reported results from the KYSA-8 study of mivocabtagene-autoleucel. Leerink told investors that these results are transformative and represent an important advancement for stiff person syndrome patients who have no approved FDA therapies and substantial unmet medical need. The firm added that it is not surprised by strength in shares and sees an "attractive" catalyst path.

Morgan Stanley

Michael Ulz

Overweight

maintain

$20 -> $25

2025-12-04

Reason

Morgan Stanley

Michael Ulz

Price Target

$20 -> $25

2025-12-04

maintain

Overweight

Reason

Morgan Stanley analyst Michael Ulz raised the firm's price target on Kyverna Therapeutics to $25 from $20 and keeps an Overweight rating on the shares. Topline data from the registrational Phase 2 study of KYV-101 in stiff person syndrome are expected in early 2026, notes the analyst, who cites "increasing conviction in the potential of KYV-101" for the firm's higher target.

Wells Fargo

Derek Archila

Overweight

maintain

$27 -> $31

2025-10-30

Reason

Wells Fargo

Derek Archila

Price Target

$27 -> $31

2025-10-30

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila raised the firm's price target on Kyverna Therapeutics to $31 from $27 and keeps an Overweight rating on the shares. The firm believes KYV-101's pivotal programs in Myasthenia Gravis and Stiff-Person Syndrome are highly de-risked and remain unappreciated by investors. Wells cites a higher probability of success for MG, and believes shares should work up into the pivotal SPS read out in the first half of 2026.

Wells Fargo

Derek Archila

Overweight

maintain

$27 -> $31

2025-10-29

Reason

Wells Fargo

Derek Archila

Price Target

$27 -> $31

2025-10-29

maintain

Overweight

Reason

Wells Fargo analyst Derek Archila raised the firm's price target on Kyverna Therapeutics to $31 from $27 and keeps an Overweight rating on the shares after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis. KYV-101's pivotal programs in MG and stiff person syndrome are "highly de-risked and remain unappreciated by investors," the analyst argues.

Valuation Metrics

The current forward P/E ratio for Kyverna Therapeutics Inc (KYTX.O) is -2.42, compared to its 5-year average forward P/E of -2.51. For a more detailed relative valuation and DCF analysis to assess Kyverna Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.51

Current PE

-2.42

Overvalued PE

-0.21

Undervalued PE

-4.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.89

Current EV/EBITDA

-1.86

Overvalued EV/EBITDA

1.98

Undervalued EV/EBITDA

-3.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KYTX News & Events

Events Timeline

No data

News

8.5

2025-12-31Benzinga

Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave

9.0

2025-12-26Benzinga

Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%

9.0

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

People Also Watch

Frequently Asked Questions

What is Kyverna Therapeutics Inc (KYTX) stock price today?

The current price of KYTX is 8.32 USD — it has decreased -1.54 % in the last trading day.

What is Kyverna Therapeutics Inc (KYTX)'s business?

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

What is the price predicton of KYTX Stock?

What is Kyverna Therapeutics Inc (KYTX)'s revenue for the last quarter?

Kyverna Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Kyverna Therapeutics Inc (KYTX)'s earnings per share (EPS) for the last quarter?

Kyverna Therapeutics Inc. EPS for the last quarter amounts to -0.85 USD, increased 6.25 % YoY.

What changes have occurred in the market's expectations for Kyverna Therapeutics Inc (KYTX)'s fundamentals?

The market is revising No Change the revenue expectations for KYTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 25.49%.

How many employees does Kyverna Therapeutics Inc (KYTX). have?

Kyverna Therapeutics Inc (KYTX) has 112 emplpoyees as of January 10 2026.

What is Kyverna Therapeutics Inc (KYTX) market cap?

Today KYTX has the market capitalization of 475.32M USD.